{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:22:00Z","timestamp":1789525320754,"version":"build-2803163510"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The decrease of bone mineral density (BMD) after the intake of Tenofovir disoproxil fumarate (TDF)-based drugs in people living with HIV\/AIDS (PLWHA) and HIV-negative key populations under pre-exposure prophylaxis (PrEP) regimen raised concerns. Previous findings on the effects of vitamin D (VD) and calcium supplements and the recovery of BMD loss were inconclusive. The optimal doses of VD and calcium and its supplementary duration remained unknown. Therefore, we conducted a systematic review and meta-analysis to synthesize current evidence on VD and calcium supplements to inform clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched PubMed, Web of Science, Cochrane library, and EMBASE databases for all placebo-controlled trials and prospective cohort studies published before March 5, 2021 that investigated VD and calcium supplements in participants taking TDF-based drugs. The keywords calcium, vitamin D, Tenofovir, and BMD were used for the searches. The primary outcome was changes of spine and hip BMD. A subgroup analysis was performed to determine the factors that were related to the effects of VD supplements on BMD. Locally weighted regression (loess) was used to determine the relationships of VD supplements, supplementary duration, and changes of BMD. This study was registered at PROSPERO (No. 42021231000).<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>Seven eligible studies including 703 participants were included in the analyses. The meta-analysis found that VD and calcium supplementation was related to a significant increase of BMD in the spine and hip [standardized mean difference (SMD) 0.43; 95% CI, 0.25 to 0.61, <jats:italic>p<\/jats:italic> = 0.009]. Moreover, positive dose-response relationships were demonstrated between doses of VD and calcium supplements, supplementary duration, and BMD recovery. Patients who took VD with the dose level of 4,000 IU\/D obtained the highest BMD improvement (SMD 0.59, 95% CI, 0.43 to 0.74). No side effects were reported on VD and calcium supplementation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interpretation<\/jats:title><jats:p>We found the VD and calcium supplementation was associated with increases of BMD in participants taking TDF-based drugs. An optimal supplementary dose of 4,000 IU\/D for VD was suggested for clinicians. The findings could be used in clinical practice to improve the BMD outcomes in people who were taking TDF-based drugs.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnut.2022.749948","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T12:33:18Z","timestamp":1648729998000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Vitamin D and Calcium Supplementation Reverses Tenofovir-Caused Bone Mineral Density Loss in People Taking ART or PrEP: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"9","author":[{"given":"Xiaoyan","family":"Bi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12981-015-0053-z","article-title":"Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand","volume":"12","author":"Manosuthi","year":"2015","journal-title":"AIDS Res Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s00198-018-4794-0","article-title":"Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis","volume":"30","author":"Biver","year":"2019","journal-title":"Osteoporosis Int."},{"key":"B3","first-page":"586","article-title":"Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults","volume":"61","year":"2012","journal-title":"MMWR Morbidity Mortality Wkly Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/23744235.2016.1247495","article-title":"Antiretroviral treatment for HIV infection: swedish recommendations 2016","volume":"49","author":"Eriksen","year":"2017","journal-title":"Infect Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1080\/09540121.2019.1622631","article-title":"Antiretroviral-na\u00efve HIV-infected patients had lower bone formation markers than HIV-uninfected adults","volume":"32","author":"Wattanachanya","year":"2020","journal-title":"AIDS Care."},{"key":"B6","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1007\/s12072-020-10030-4","article-title":"Suboptimal response, elder and comorbidity are decisive elements for choosing tenofovir alafenamide (TAF): a real-world study in southwest of China","volume":"14","author":"Zhang","year":"2020","journal-title":"Hepatol Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1086\/656417","article-title":"Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study","volume":"51","author":"Stellbrink","year":"2010","journal-title":"Clin infect Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1097\/QAD.0b013e328328f789","article-title":"Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients","volume":"23","author":"Duvivier","year":"2009","journal-title":"AIDS."},{"key":"B9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00198-020-05584-w","article-title":"Longitudinal change in bone mineral density among Chinese individuals with HIV after initiation of antiretroviral therapy","volume":"32","author":"Guo","year":"2021","journal-title":"Osteoporosis Int."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1097\/CM9.0000000000001317","article-title":"Prevalence and risk factors for bone mineral density changes in antiretroviral therapy-naive human immunodeficiency virus-infected adults: a Chinese cohort study","volume":"133","author":"Zeng","year":"2020","journal-title":"Chin Med J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/cid\/ciz486","article-title":"Changes in bone mass after discontinuation of preexposure prophylaxis with tenofovir disoproxil fumarate\/emtricitabine in young men who have sex with men: extension phase results of adolescent trials network protocols 110 and 113","volume":"70","author":"Havens","year":"2020","journal-title":"Clin Infect Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0230368","DOI":"10.1371\/journal.pone.0230368","article-title":"Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: a five-year prospective study","volume":"15","author":"Han","year":"2020","journal-title":"PLoS ONE."},{"key":"B13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2174\/1570162X18999200917120449","article-title":"Association between nonalcoholic fatty liver disease and bone mineral density in HIV-infected patients receiving long-term TDF-based antiretroviral therapy","volume":"19","author":"Xu","year":"2021","journal-title":"Curr HIV Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1016\/S2352-3018(19)30293-0","article-title":"PrEP in China: choices are ahead","volume":"7","author":"Xu","year":"2020","journal-title":"Lancet HIV."},{"key":"B15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ijid.2020.06.037","article-title":"Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate","volume":"97","author":"Cressey","year":"2020","journal-title":"Int J Infect Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.17219\/acem\/127684","article-title":"Effects of efavirenz and tenofovir on bone tissue in Wistar rats","volume":"29","author":"Matuszewska","year":"2020","journal-title":"Adv Clin Exp Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"ofz338","DOI":"10.1093\/ofid\/ofz338","article-title":"Impact of tenofovir-based pre-exposure prophylaxis on biomarkers of bone formation, bone resorption, and bone mineral metabolism in HIV-negative adults","volume":"6","author":"Nickolas","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1002\/art.41108","article-title":"1,25D3 promotes mineralization of osteoblasts by activating C\/EBP\u03b2-DKK1 axis","volume":"71","author":"Jo","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1080\/15284336.2018.1525841","article-title":"Bone mass preservation with high-dose cholecalciferol and dietary calcium in HIV patients following antiretroviral therapy. Is it possible?","volume":"19","author":"Mela","year":"2018","journal-title":"HIV Clin Trials."},{"key":"B20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S2055-6640(20)30234-X","article-title":"Effect of calcium and vitamin D supplementation on bone mineral accrual among HIV-infected Thai adolescents with low bone mineral density","volume":"4","author":"Puthanakit","year":"2018","journal-title":"J Virus Eradic."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e25624","DOI":"10.1002\/jia2.25624","article-title":"Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis","volume":"23","author":"Pornpaisalsakul","year":"2020","journal-title":"J Int AIDS Soc."},{"key":"B22","unstructured":"2011"},{"key":"B23","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1310\/hct1306-350","article-title":"Treatment of calcium and vitamin D deficiency in HIV-positive men on tenofovir-containing antiretrovial therapy","volume":"13","author":"Bech","year":"2012","journal-title":"HIV Clin Trials."},{"key":"B24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/cid\/cix753","article-title":"Vitamin D3 supplementation increases spine bone mineral density in adolescents and young adults with human immunodeficiency virus infection being treated with tenofovir disoproxil fumarate: a randomized, placebo-controlled trial","volume":"66","author":"Havens","year":"2018","journal-title":"Clin Infect Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"815","DOI":"10.7326\/M14-1409","article-title":"Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: a randomized trial","volume":"162","author":"Overton","year":"2015","journal-title":"Ann Intern Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2174\/1570162X18666200106150806","article-title":"Vitamin D and calcium supplement attenuate bone loss among HIV infected patients receiving tenofovir disoproxil fumarate\/emtricitabine\/ efavirenz: an open-label, randomized controlled trial","volume":"18","author":"Boontanondha","year":"2020","journal-title":"Curr HIV Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"S220","DOI":"10.1093\/ofid\/ofx163.452","article-title":"Exploring strategies for attenuating changes in bone mineral density in MSM on TDF\/FTC HIV pre-exposure prophylaxis","volume":"4","author":"Kortenaar","year":"2017","journal-title":"Open Forum Infect Dis."},{"key":"B28","unstructured":"2021"},{"key":"B29","doi-asserted-by":"publisher","first-page":"684782","DOI":"10.3389\/fphys.2021.684782","article-title":"Objectively measured physical activity is associated with body composition and metabolic profiles of pacific and new zealand european women with different metabolic disease risks","volume":"12","author":"Slater","year":"2021","journal-title":"Front Physiol."},{"key":"B30","unstructured":"WellsGA\n            SheaB\n            O'ConnellD\n            PetersonJ\n            WelchV\n            LososM\n          25652605The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomised Studies in Meta-Analyses."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1093\/infdis\/jir188","article-title":"Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202","volume":"203","author":"McComsey","year":"2011","journal-title":"J Infect Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA."},{"key":"B33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3851\/IMP1502","article-title":"Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D","volume":"15","author":"Brown","year":"2010","journal-title":"Antiviral Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2352-4642(17)30009-3","article-title":"Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial","volume":"1","author":"Natukunda","year":"2017","journal-title":"Lancet Child Adolesc Health."},{"key":"B35","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ijid.2020.01.035","article-title":"Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: a meta-analysis of randomized controlled trials","volume":"93","author":"Tao","year":"2020","journal-title":"Int J Infect Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bcp.2017.11.023","article-title":"Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections","volume":"153","author":"De Clercq","year":"2018","journal-title":"Biochem Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV Infection in adults: 2020 recommendations of the international antiviral society-USA panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA."},{"key":"B38","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40121-020-00384-5","article-title":"Patient-focused selection of PrEP medication for individuals at risk of HIV: a narrative review","volume":"10","author":"Fields","year":"2021","journal-title":"Infect Dis Ther."}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2022.749948\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T12:33:25Z","timestamp":1648730005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2022.749948\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":38,"alternative-id":["10.3389\/fnut.2022.749948"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2022.749948","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"article-number":"749948"}}